Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 458,578 | 178,494 | 166,797 | 212,527 | 196,830 |
| Cost of Goods | 24,531 | 13,626 | 34,360 | 40,857 | 33,557 |
| Gross Profit | 434,047 | 164,868 | 132,437 | 171,670 | 163,273 |
| Operating Expenses | 211,395 | 198,780 | 216,125 | 198,693 | 211,110 |
| Operating Income | 223,183 | -33,286 | -83,328 | -26,166 | -47,280 |
| Interest Expense | 11,279 | 11,152 | 11,049 | 11,533 | 12,532 |
| Other Income | 4,413 | 2,753 | 2,493 | 1,632 | 2,959 |
| Pre-tax Income | 216,317 | -41,685 | -91,884 | -36,067 | -56,853 |
| Income Tax | 602 | 466 | 341 | 286 | 592 |
| Net Income Continuous | 215,715 | -42,151 | -92,225 | -36,353 | -57,445 |
| Net Income | $215,715 | $-42,151 | $-92,225 | $-36,353 | $-57,445 |
| EPS Basic Total Ops | 1.71 | -0.33 | -0.74 | -0.30 | -0.46 |
| EPS Basic Continuous Ops | 1.71 | -0.33 | -0.74 | -0.29 | -0.46 |
| EPS Diluted Total Ops | 1.67 | -0.33 | -0.74 | -0.30 | -0.46 |
| EPS Diluted Continuous Ops | 1.66 | -0.33 | -0.74 | -0.29 | -0.46 |
| EPS Diluted Before Non-Recurring Items | 1.67 | -0.33 | -0.74 | -0.29 | -0.46 |
| EBITDA(a) | $224,158 | $-32,226 | $-82,291 | $-16,196 | $-55,101 |